Cargando…
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients
V565 is an engineered TNFα-neutralising single domain antibody formulated into enteric coated mini-tablets to enable release in the intestine after oral administration as a possible oral treatment for inflammatory bowel disease (IBD). Following oral administration, ileal recovery of V565 was investi...
Autores principales: | Nurbhai, Suhail, Roberts, Kevin J., Carlton, Timothy M., Maggiore, Luana, Cubitt, Marion F., Ray, Keith P., Reckless, Jill, Mohammed, Hafeez, Irving, Peter, MacDonald, Thomas T., Vossenkämper, Anna, West, Michael R., Parkes, Gareth C., Crowe, J. Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773840/ https://www.ncbi.nlm.nih.gov/pubmed/31575982 http://dx.doi.org/10.1038/s41598-019-50545-x |
Ejemplares similares
-
Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease
por: Crowe, J. Scott, et al.
Publicado: (2018) -
Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease
por: Roberts, Kevin J., et al.
Publicado: (2021) -
565 Sensitization Profile in Severe Asthma
por: Bozek, Andrzej, et al.
Publicado: (2012) -
POS-565 ARTERIOVENOUS FISTULA BY NEPHROLOGIST IN COVID ERA
por: Bhargava, V., et al.
Publicado: (2021) -
565 Impact of Municipal Ordinances on Firework-Related Injuries
por: Mefford, Austin T, et al.
Publicado: (2022)